The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
